title: Acute myeloid leukemia and myelodysplasia in patients with chronic lymphocytic leukemia receiving fludarabine as initial therapy.
authors.forename: D
authors.initials: D
authors.lastname: Coso
authors.forename: R
authors.initials: R
authors.lastname: Costello
authors.forename: R
authors.initials: R
authors.lastname: Cohen-Valensi
authors.forename: D
authors.initials: D
authors.lastname: Sainty
authors.forename: M
authors.initials: M
authors.lastname: Nezri
authors.forename: J A
authors.initials: JA
authors.lastname: Gastaut
authors.forename: R
authors.initials: R
authors.lastname: Bouabdallah
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001853:Bone Marrow / Q000187:drug effects; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced* / Q000175:diagnosis; D008297:Male; D009190:Myelodysplastic Syndromes / Q000139:chemically induced* / Q000175:diagnosis; D014740:Vidarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine